had similar 1-year ST and TLR rates compared with a conformal durable polymer-based EES (9) . However, the underlying stent platforms varied substantially in this trial. Thus, whether the safety and efficacy profiles of BP-DES and durable polymer DES inherently differ requires additional study.
Moreover, the optimal rates of drug elution and polymer bioabsorption from BP-DES are unknown. In this regard, the development of 2 DES has enabled assessment of the potential clinical effects of different drug elution and polymer absorption profiles. Specifically, the widely used polylactide (PLA) polymer-based Excel stent (JW Medical, Weihai, China) is a laser-cut 316L stainless steel SES, characterized by complete drug elution within 180 days and complete PLA polymer absorption within 6 to 9 months (10). In contrast, the novel poly-lactideco-glycolide (PLGA) polymer-based BuMA stent (Sino Medical, Tianjin, China) is a laser-cut 316L stainless steel SES with a unique design that incorporates an electrografting base layer between the polymer and stent strut, allowing for complete elution of sirolimus within 30 days and complete absorption of the PLGA polymer within 3 months (11).
A prior single-center, randomized trial showed that the BuMA SES had superior strut coverage at 3 months compared with the Excel SES, as assessed by optical coherence tomography (OCT) (11 Values are mean AE SD or n (%). *Number of patients for whom continuous variables were calculated. †Renal insufficiency was defined as an estimated glomerular filtration rate <30 ml/min/1.73 m 2 of body surface area or the need for dialysis. ‡Peripheral arterial disease includes lower extremity peripheral artery disease, abdominal aortic aneurysm, renal and mesenteric artery disease, and extracranial carotid artery disease. §Number of lesions for which continuous variables were calculated. kPatients with B2/C lesions were classified according to the criteria of the ACC/AHA if 1 or more treated lesions met these criteria.
ACC ¼ American College of Cardiology; AHA ¼ American Heart Association; L ¼ number of target lesions; NSTEMI ¼ non-ST-segment elevation myocardial infarction; STEMI ¼ ST-segment elevation myocardial infarction; SYNTAX ¼ Synergy Between PCI With TAXUS and Cardiac Surgery.
All adverse events were adjudicated by a blinded clinical events committee, and angiograms were reviewed by a blinded independent core laboratory (CCRF, Beijing, China). Details of the study organization and participating centers are listed in the Online Appendix.
STATISTICAL ANALYSIS. The trial was powered for sequential testing of noninferiority and superiority for the primary endpoint at 1 year. For noninferiority testing, an 8.3% event rate was assumed for both groups on the basis of the event rates from a previously reported all-comers study (13) . With a noninferiority margin of 3.5%, enrolling 2,350 patients and anticipating 5% loss to follow-up yielded 85% power to demonstrate noninferiority with a 1-sided type I error of 0.025. Superiority testing was pre-specified if the noninferiority for TLF was met. Assuming a 1-year TLF rate of 8.3% in the Excel group and 5.3% in the BuMA group (a clinically meaningful 36% relative reduction), the study had 80% power to demonstrate superiority with a 2-sided type I error of 0.05. Values are n (%) or mean AE SD. *The value is the difference in the BuMA group compared with the Excel group. †Number of lesions for which continuous variables were calculated. ‡Number of patients for whom continuous variables were calculated. §Definitions for device, lesions, and procedural success are provided for the prespecified endpoints in the definitions section of the Online Appendix. Time-to-event curves depict the primary endpoint and definite/probable stent thrombosis through 1 year. Analyses were performed in the intention-to-treat population. Kaplan-Meier curves show the cumulative incidence of (A) target lesion failure (TLF) (the primary endpoint); and (B) definite/probable stent thrombosis. CI ¼ confidence interval; HR ¼ hazard ratio; ST ¼ stent thrombosis. 
Dual antiplatelet therapy (DAPT) utilization rates
during hospitalization and at follow-up were high and were comparable in both groups (Online Table 4 ). Table 5 ). The 1-year relative rates of TLF were consistent across the examined pre-specified subgroups ( Figure 2) . The PoCE at 1 year occurred in 9.6% and 8.5% of patients in the BuMA and Excel groups, respectively (log-rank p ¼ 0.31). The individual components of the PoCE also did not significantly vary between devices, except that patients in the BuMA group had a borderline significantly higher rate of any revascularization (4.4% vs. 2.9%; log-rank p ¼ 0.05).
Similar results were found in the PTE population (Online Table 6 , Online Figure 2 ).
STENT THROMBOSIS. At 1 year, the rate of definite/probable ST was lower in BuMA-assigned patients compared with Excel-assigned patients (0.5% vs. 1.3%; log-rank p ¼ 0.048). The difference in ST favoring the BuMA stent was stronger in the PTE cohort (0.4% vs. 1.3%; log-rank p ¼ 0.01) (Online Table 6 ).
Time-to-event analysis showed that the curves separated principally within the first 3 months (Online Figures 3 and 4) , and were significantly different in the subacute period (>24 h to 30 days) ( Table 3 Values are n (%). *1-year follow-up includes a window of AE 30 days. †Target lesion failure was defined as a composite of cardiac death, target vessel MI, or ischemia-driven TLR. ‡Patient-oriented composite endpoint was defined as a composite of all-cause death, all MI, or any revascularization. Percentages were Kaplan-Meier estimates from the intention-to-treat analysis. A log-rank test was used to calculate p values.
MI ¼ myocardial infarction; TLR ¼ target lesion revascularization; TVR ¼ target vessel revascularization; other abbreviations as in Tables 1 and 2. with contemporary durable polymer DES, especially the cobalt chromium EES (8) other abbreviations as in Figure 1 .
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